logo-loader

'Customer data validates strategy' for cancer diagnostic, says ANGLE PLC boss Andrew Newland

Last updated: 15:15 04 Apr 2017 BST, First published: 10:15 04 Apr 2017 BST

Andrew Newland, founder of ANGLE PLC (LON:AGL, OTCQX:ANPCY) runs Proactive through research carried out by the University of Athens and Attikon University Hospital which has found that their Parsortix system out-performs existing technology and, for the first time, is able to harvest head and neck cancer cells from patient blood for analysis.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24